Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 8, 2006
Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1F Gilli, F Marnetto, M Caldano, et al.Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|January 3, 2006
Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatmentsS Malucchi, M Capobianco, F Gilli, et al.Journal of Immunological Methods|March 6, 2007
Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-betaA Bertolotto, A Sala, M Caldano, et al.Journal of Neuroimmunology|December 14, 2004
Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosisF Gilli, F Marnetto, M Caldano, et al.European Journal of Neurology|December 20, 2018
Study of the NR4A family gene expression in patients with multiple sclerosis treated with FingolimodF Montarolo, S Perga, S Martire, et al.Journal of Neurology, Neurosurgery, and Psychiatry|August 18, 2004
Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodiesA Bertolotto, A Sala, S Malucchi, et al.Neurology|October 31, 2008
Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosisF Gilli, P Valentino, M Caldano, et al.Neurology|February 15, 2008
Predictive markers for response to interferon therapy in patients with multiple sclerosisS Malucchi, F Gilli, M Caldano, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|February 1, 2007
Qualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosisF Gilli, F Hoffmann, A Sala, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|September 23, 2008
Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practiceL F van der Voort, A Kok, A Visser, et al.Pageof 2